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Background: Childhood obesity has been suggested as a risk factor for bronchial asthma. The aim of this study was to clar-
ify the relationship between clinical factors related to obesity, including adipocytokines and eosinophilic inflammation, as
candidate pathogenesis mechanisms of bronchial asthma in Japanese children and adolescents.
Methods: Forty-one children and adolescents visiting our outpatient clinic were enrolled. The relationship between partici-
pants’ clinical and demographic characteristics and fraction of exhaled nitric oxide (FENO) or blood eosinophil (B-Eos)
count values were analyzed.
Results: No significant correlation was observed between either FENO or B-Eos count values and the body mass index z-
score. FENO was high (35 ppb) in 8 cases and normal (<35 ppb) in 33 cases. Adiponectin was significantly lower in the
high FENO group than in the normal FENO group (6.5 vs. 8.1 μg/mL, p<0.02). A negative correlation between B-Eos count
values and adiponectin levels (r=−0.34, p<0.05) and a positive correlation between B-Eos count values and plasminogen acti-
vator inhibitor-1 levels were noted (r=0.42, p<0.01). The univariable odds ratio of adiponectin for high FENO was 0.62
(0.41-0.95) and the association was borderline after adjusting for B-Eos.
Conclusions: Eosinophilic inflammation was associated with a decrease in serum adiponectin levels which may be induced
by visceral fat accumulation.
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Introduction
Obesity is well known as a major risk factor for the de-
velopment of bronchial asthma.
１-３
However, the mecha-
nisms involved in this relationship remain unclear. In-
flammatory changes within adipose tissue of adult
women with obesity could contribute to airway inflam-
mation and airway reactivity in individuals with obesity.
４
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In later childhood, childhood bronchial asthma is mainly
caused by eosinophilic inflammation of the airway. How-
ever, the pathological association between body fat accu-
mulation and eosinophilic inflammation of the airway is
unclear, in particular, in children.
Boulet asserted that low-grade systemic inflammation
caused by adipocytokines and oxidative stress is a risk
factor for bronchial asthma.
５
In adipocytokines, adi-
ponectin and leptin play an important role in low-grade
inflammation. Adiponectin, an insulin-sensitizing hor-
mone, has predominantly anti-inflammatory and antioxi-
dative effects.
６
Adiponectin has receptors in the respira-
tory epithelium and smooth airway muscles.
７，８
Adi-
ponectin levels are decreased in Japanese children with
obesity who have high visceral fat accumulation.
９
Leptin, an interleukin ( IL ) -6-like adipocytokine se-
creted from adipocytes, promotes inflammation and oxi-
dative stress. Leptin receptors are present in the respira-
tory epithelium, submucosal space, and activated lym-
phocytes in the lung.
１０，１１
Leptin levels increase in propor-
tion to subcutaneous fat accumulation.
１２
In fact, among
middle-aged women, an increase in leptin levels has been
related to bronchial asthma.
１３
Plasminogen activator inhibitor-1 (PAI-1), an adipocy-
tokine, plays an important role in a range of physiologi-
cal and pathological processes, including fibrinolysis, co-
agulation, inflammation, and wound healing. PAI-1 lev-
els are elevated in insulin-resistant subjects and are asso-
ciated with an increased cardiovascular risk of
atherothrombosis.
１４，１５
Several studies have suggested that
visceral adipose tissue is the major component affecting




demonstrated that the plasma PAI-1 levels of Japanese
children and adolescents with obesity were significantly
correlated with immunoreactive insulin, homeostasis
model assessment insulin resistance, and quantitative in-
sulin sensitivity check index values.
１７
Obesity is heterogeneous in children; its characteristics
depend on the distribution of visceral and subcutaneous
fat accumulation. The heterogeneity of simple obesity in
terms of insulin resistance in Japanese children and ado-
lescents has been previously demonstrated.
１８
In the pre-
sent study, we hypothesized that eosinophilic inflamma-
tion of the airway in children with obesity may be differ
between visceral fat-dominant obesity or subcutaneous
fat-dominant types of obesity. If eosinophilic inflamma-
tion of the airway is largely influenced by visceral fat,
this type of inflammation might be associated with the
presence of adiponectin and PAI-1. In contrast, if eosino-
philic inflammation of the airway is influenced mainly by
subcutaneous fat, this type of inflammation might be as-
sociated with the presence of leptin.
Malinovschi et al. have reported fraction of exhaled ni-
tric oxide (FENO) and blood eosinophil (B-Eos) counts
as independent risk factors for bronchial asthma.
１９
FENO
is mainly triggered by IL-4 and IL-13 and indicates
eosinophilic inflammation of the airway. B-Eos is mainly
triggered by IL-5 and indicates eosinophilic inflamma-
tion of the whole body.
１９-２１
In the present study, we investigated the association
between adiponectin, leptin, PAI-1, and oxidative stress
levels, and eosinophilic inflammation of the airway in
children with obesity by measuring FENO and B-Eos
counts.
Materials and Methods
1. Subjects and study design
We conducted a cross-sectional observational study
with Japanese children and adolescents aged 6-15 years.
Subjects were recruited from among patients who at-
tended our outpatient clinic (Tokyo Women’s Medical
University Medical Center East, Tokyo, Japan) for treat-
ment of obesity or an allergy-related disease (bronchial
asthma, atopic dermatitis, food allergy) between Septem-
ber 2013 and August 2016. No limitations were placed
on the weight of potential participants; however, partici-
pants with moderate or severe obesity were expected to
be included. The exclusion criteria were: (1) use of in-
haled or nasal corticosteroids in the 4 weeks before study
participation, as corticosteroids reduce inflammation; (2)
presence of endocrine metabolic diseases (e.g., diabetes
mellitus), as these diseases can induce systematic inflam-
mation; and (3) infection within 1 month before recruit-
ment, as it would preclude distinguishing between infec-
tion and obesity as the cause of systematic inflammation.
All data were collected 1-2 weeks after participant re-
cruitment.
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2. Tests and data collection
Medical history regarding bronchial asthma, allergic
rhinitis, atopic dermatitis, and food allergies was ob-
tained from the participants’ parents. All participants vis-
ited our outpatient clinic in the morning after an over-
night fast. Body height, weight, waist circumference,
blood pressure, and body fat percentage were measured;
14 mL blood samples were also collected. Participants
were required to remove their shoes and outer clothes for
the measurements of body height and weight. Partici-
pants were asked to stand, take off their clothes, and
breathe out slightly during the measurement of waist cir-
cumference, which was collected at the level of the um-
bilicus. Body mass index (BMI) was calculated as the
weight in kilograms divided by the square of the height
in meters (kg/m
2
). The reference used for the calculation
of the standard deviation score for BMI was based on the
data from Japanese children published in 2000.
２２
For
blood pressure measurements, participants were required
to sit in a relaxed state. Body fat percentage was deter-
mined using dual-energy X-ray absorptiometry (Lunar
iDXA, GE Healthcare, Japan).
FENO was measured using the NIOX MINO
Ⓡ
(Aero-
crine, Solna, Sweden), an electrochemical sensor device,
according to the guidelines of the American Thoracic So-
ciety (ATS) Committee on interpretation of FENO levels
for clinical applications.
２３
Participants were required to
exhale for 10 seconds at an exhalation pressure of 10-20
cmH2O to maintain a stable flow rate of 50±5 mL/s,
which is the standardized measurement for lower respira-
tory tract FENO agreed upon by the European Respira-
tory Society and ATS.
２４
A calibrated electrochemical sen-
sor was used to evaluate the final 3 seconds of the exha-
lation ; the results were expressed in parts per billion
(ppb) with a range between 5 and 300 ppb.
２５
In the blood examination, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), γ-glutamyl tran-
speptidase (γ-GTP), triglycerides (TGs), total cholesterol,
high-density lipoprotein (HDL ) cholesterol, uric acid,
and blood glucose levels were measured using an auto-
mated analyzer ( Labospect008, Hitachi High-
Technologies, Tokyo, Japan ) . Immunoreactive insulin
level was measured using a chemiluminescent enzyme
immunoassay (Lumipulse Presto II, Fujirebio Inc. , To-
kyo, Japan). Low-density lipoprotein (LDL) cholesterol
level was calculated using the Friedewald equation.
Leptin (double-antibody radioimmunoassay method us-
ing a γ-counter), adiponectin (latex immunoassay turbidi-
metric method [Biomajesty JCA BM8000 series, Japan
Electronics Co., Ltd, Tokyo, Japan]), and PAI-1 (latex
coagulation method [Biomajesty JCA-BM 9130, Japan
Electronics Co. , Ltd, Tokyo, Japan]) levels were also
measured. Malondialdehyde-modified low-density lipo-
protein (MDA-LDL) cholesterol level was measured as
an oxidative stress marker. B-Eos values were measured
using an automated analyzer ( XN-3000, Sysmex,
Okayama, Japan) . The total immunoglobulin E ( IgE )
level was measured using a fluorescence enzyme immu-
noassay (Phiadia5000, Thermo Fisher Diagnostics, Mas-
sachusetts, USA), and high-sensitivity C-reactive protein
level was measured using nephelometry (BN II, Siemens
Healthcare Diagnostics, New York, USA).
3. Statistical analysis
Participants were divided into two groups (FENO-low:
<35 ppb and FENO-high: 35 ppb), following the ATS
clinical guidelines on FENO measurements.
２３
We com-
pared the baseline characteristic of these groups using the
Wilcoxon rank sum test and Fisher’s exact test. Pearson’s
correlation coefficient was used to calculate univariable
correlation coefficients for FENO and B-Eos, and other
variables. In addition, we fitted a logistic regression
model for high-FENO (35 ppb) group. The variables of
p value <0.1 in the single correlation coefficient with
FENO were put on the calculation. We selected the vari-
ables for the multivariable logistic regression model for
the high-FENO group in a stepwise selection process,
whereby the factors that met Akaike’s minimum infor-
mation criterion (AIC) were considered the best match.
Then, multivariable logistic regression model was used to
calculate odds ratios. Two-tailed p values <0.05 were
considered statically significant. JMP Pro 15 (SAS Insti-
tute, Cary, NC, USA) was used for statistical analyses.
4. Ethics
Written informed consent to participate in this study
was obtained from patients’ parents, and assents were
provided. This study was conducted with the approval of
the Institutional Review Board of Tokyo Women’s Medi-
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Figure 1 Distribution of BMI-z score for the present study par-
ticipants.
BMI-z score, body mass index-z score.
Table　1　Baseline characteristics of study participants.
Characteristic Value
Patients, n 41
Age, y (median, IQR) 6-15 (10, 9-12.5)
Male, n (%) 29 (71)
BMI-z score, median (IQR) 1.9 (-1-3.5)
Medical history of bronchial asthma, n (%) 5 (12)
 Using inhaled corticoid steroid, n (%) 0 (0)
Medical history of allergic rhinitis, n (%) 21 (51)
 Using nasal drop corticoid steroid, n (%) 0 (0)
Medical history of food allergy, n (%) 4 (10)
Medical history of atopic dermatitis, n (%) 7 (17)
No medical history of allergy, n (%) 8 (19.5)
Smoker of patient’s household, n (%) 24 (59)
BMI-z score, body mass index-z score; IQR, interquartile range.
cal University in accordance with the Declaration of Hel-
sinki (approval number: 130818).
Results
1. Clinical and demographic characteristics
Forty-one participants, including 29 ( 70.7% ) male,
aged 6-15 years (median 10 years, interquartile range
[ IQR ] : 9-12.5 ) were recruited. Participants’ baseline
characteristics are shown in Table 1; BMI-z score distri-
bution is shown in Figure 1. BMI-z scores ranged from −
1.0 to 3.5 (median 1.9). In five (12.2%) cases, the BMI-z
score was2.5, and these cases were classified as severe
obesity. In 19 (46.3%) cases, the BMI-z score was 2.0,
and these cases were classified as moderate obesity.
Twenty-one (51.2%) patients had allergic rhinitis. Five
(12.2%) patients had bronchial asthma, and none had un-
dergone inhaled corticosteroid therapy. Twenty patients
(48.8%) had an overlapping allergy disease. Eight pa-
tients (19.5%) had no allergic disease.
2. Low-FENO (<35 ppb) vs. high-FENO (35 ppb)
groups
Thirty-three (80.5%) and eight (19.5%) participants
were included in the low- and high-FENO groups, re-
spectively (Table 2). The prevalence of allergic rhinitis
was 48.5% (n=16) and 62.5% (n=5) in the low- and high-
FENO groups, respectively (p=0.5). The median BMI-z
score was 1.8 and 2.0 in the low- and high-FENO
groups, respectively (p=0.7), indicating that BMI-z score
was not associated with FENO. The median waist cir-
cumference was 81 cm and 87 cm in the low- and high-
FENO groups, respectively (p=0.07).
The median B-Eos values were significantly higher in
the high-FENO group (343/μL, IQR: 231-703/μL) than
in the low-FENO group (184/μL, IQR: 80-279/μL) (p=
0.004).
As for adipocytokines, only adiponectin levels signifi-
cantly differed between the groups. The median levels of
serum adiponectin were significantly lower in the high-
FENO group (6.5 ng/mL) than in the low-FENO group
(8.1 ng/mL) (p=0.0142) (Table 2). Leptin and PAI-1 lev-
els did not differ significantly between the two groups (p
=0.8 and p=0.6, respectively).
The median values of the MDA-LDL/LDL ratio as a
marker of oxidative stress were 0.59 and 0.65 in the low-
FENO and high-FENO groups, respectively (p=0.07) .
HDL cholesterol, LDL cholesterol, TG, AST, ALT,
AST/ALT ratio, γ-GTP, uric acid, insulin, IgE, and high-
sensitivity C-reactive protein levels did not differ signifi-
cantly between the two groups.
3. Univariable correlation coefficient with FENO
In univariable correlation analyses, B-Eos (r=0.58, p<
0.0001) and uric acid (r=0.34, p=0.03) were significantly
correlated with FENO (Table 3). Adiponectin levels (r
=−0.26, p=0.09) and leptin/adiponectin ratio (r=0.27, p=
0.09) tended to correlate with FENO, but this finding did
not meet the threshold for statistical significance. Scatter
plot diagrams capturing univariate correlations between
FENO and several explanatory variables are shown in
Figure 2. The BMI-z score was not significantly corre-
lated with FENO.
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Table　2　Comparison between the low-FENO (<35 ppb) and high-FENO (≥35 ppb) groups.
FENO <35 ppb, n=33 FENO ≥35 ppb, n=8 p-value
Age,  (median) 10 12 0.1
Male, n (%) 21 (64) 8 (100) 0.08
Allergic rhinitis, n (%) 16 (48) 5 (62.5) 0.5
Bronchial asthma, n (%) 1 (3) 4 (50) 0.03*
Food allergy, n (%) 3 (9) 0 (0) 1.0
Atopic dermatitis, n (%) 5 (15) 2 (25) 0.6
Smokers in patient’s household, n (%) 20 (60) 4 (50) 0.6
BMI-z score, median (IQR) 1.8 (1.3-2.7) 2.0 (1.7-2.3) 0.7
Waist circumference (cm), median (IQR) 81 (71-94) 87 (85-104) 0.07
Waist circumference/height ratio, median (IQR) 0.55 (0.51-0.63) 0.59 (0.51-0.64) 0.6
Systolic blood pressure (mmHg), median (IQR) 117 (106-123) 111 (104-113) 0.1
Diastolic blood pressure (mmHg), median (IQR) 66 (60-74) 62.5 (60-84) 0.9
Body fat percentage (%), median (IQR) 43 (38-47) 44 (33-48) 0.9
IgE (U/mL), median (IQR) 115 (42-221) 207 (124-287) 0.1
Blood eosinophil counts (/μL), median (IQR) 184 (80-279) 343 (231-703) 0.004*
Leptin (ng/mL), median (IQR) 22 (12-31) 20 (9-32) 0.8
Adiponectin (ng/mL), median (IQR) 8.1 (6.4-10.3) 6.5 (3.9-7.4) 0.01*
Leptin/adiponectin ratio, median (IQR) 2.7 (1.6-4.6) 3.7 (1.3-9.1) 0.5
PAI-1 (ng/mL), median (IQR) 30 (20-43) 34 (20-46) 0.6
MDA-LDL cholesterol/LDL cholesterol ratio (mU/mg), median (IQR) 0.59 (0.5-0.69) 0.65 (0.62-0.70) 0.07
High-sensitivity CRP (μg/dL), median (IQR) 792 (175-2,005) 1,620 (355-4,408) 0.2
HDL cholesterol (mg/dL), median (IQR) 55 (48-64) 53 (40-62) 0.4
LDL cholesterol (mg/dL), median (IQR) 94.8 (77-120) 100.4 (77-138) 0.6
TG (mg/dL), median (IQR) 71 (56-108) 83.5 (58-122) 0.6
AST (U/L), median (IQR) 25 (19-32) 23 (28-29) 0.7
ALT (U/L), median (IQR) 22 (16-48) 36 (17-61) 0.5
AST/ALT ratio, median (IQR) 0.9 (0.63-1.4) 0.7 (0.43-1.0) 0.2
γ-GTP (U/L), median (IQR) 17 (13-28) 24 (14-46) 0.2
Uric acid (mg/dL), median (IQR) 5.5 (4.7-6.5) 6.3 (5.1-8.4) 0.2
Insulin (μIU/mL), median (IQR) 10 (7.5-15.2) 17 (7.3-18.6) 0.5
Blood glucose (mg/dL), median (IQR) 95 (93-102) 96 (88-97) 0.6
FENO, fractional exhaled nitric oxide; BMI-z score, body mass index-z score; IQR, interquartile range; IgE, immunoglobulin E; PAI-1, 
plasminogen activator inhibitor-1; MDA-LDL, malondialdehyde-modified low-density lipoprotein; LDL, low-density lipoprotein; CRP, 
C-reactive protein; HDL, high-density lipoprotein; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
γ-GTP, γ-glutamyl transpeptidase.
4. Univariable correlation coefficient with B-Eos
In the univariable analysis, IgE (r=0.59, p<0.0001),
adiponectin (r=−0.34, p=0.03), the leptin/adiponectin ra-
tio (r=0.32, p=0.004), PAI-1 (r=0.42, p=0.006), TG (r=
0.33, p=0.04), the AST/ALT ratio (r=−0.36, p=0.02), and
γ-GTP (r=0.41, p=0.01 ) were significantly correlated
with B-Eos (Table 4) . Scatter plot diagrams capturing
these associations are shown in Figure 3.
5. Logistic regression model for the high-FENO
group
In the univariable analysis, B-Eos, adiponectin, leptin/
adiponectin ratio, and urine acid were significantly asso-
ciated with FENO (p< 0.1). The stepwise selection proc-
ess revealed the combination of B-Eos and adiponectin as
the best-matched logistic regression model for the high-
FENO group. The AIC score was 29.52 and was lowest
in case of the combination of B-Eos and adiponectin. In
the multivariable logistic regression model, the odds ra-
tios for B-Eos and adiponectin were 1.055 (95% confi-
dence interval [CI] 1.0004-1.11) and 0.7 (95% CI 0.45-
1.09) respectively (Table 5).
Discussion
To our knowledge, this is the first study to reveal the as-
sociation of adipocytokines and oxidative stress in bron-
chial asthma based on the measurement of FENO in
Japanese children and adolescents with obesity.
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Table　3　Univariable correlations between FENO and explanatory variables.
r p-value
BMI-z score 0.09 0.6
Waist circumference 0.19 0.2
Waist circumference/height ratio 0.04 0.8
Systolic blood pressure -0.11 0.5
Diastolic blood pressure -0.004 0.9
Body fat percentage 0.03 0.8
IgE 0.15 0.3
Peripheral blood eosinophil counts 0.58 <0.0001*
Leptin -0.093 0.6
Adiponectin -0.26 0.09
Leptin/adiponectin ratio 0.27 0.09
PAI-1 0.2 0.2
MDA-LDL cholesterol/LDL cholesterol ratio 0.26 0.1
High-sensitivity CRP 0.085 0.6
HDL cholesterol 0.002 0.9




AST/ALT ratio -0.22 0.2
γ-GTP 0.17 0.3
Uric acid 0.34 0.03*
HbA1c -0.096 0.6
Insulin 0.13 0.4
Blood glucose -0.042 0.8
FENO, fractional exhaled nitric oxide; BMI-z score, body mass index-z score; 
IgE, immunoglobulin E; PAI-1, plasminogen activator inhibitor-1; MDA-LDL, 
malondialdehyde-modified low-density lipoprotein; LDL, Low-density lipopro-
tein; CRP, C-reactive protein; HDL, high-density lipoprotein; TG, triglycerides; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, 
γ-glutamyl transpeptidase; HbA1c, hemoglobin A1c.
Notably, there was no significant correlation between
FENO and BMI-z score or between B-Eos and BMI-z
score. These results suggest that the degree of obesity as-
sessed by body weight and height is not associated with
eosinophilic inflammation of the airway and the whole
body. Similar results have been reported in previous
studies.
２６，２７
For example, Santamaria et al. have reported
no significant difference in FENO between children with
obesity (mean FENO: 12.5 ppb, n=50) and children with
normal weight (mean FENO: 10.8 ppb, n=50).
２７
In the present study, we have demonstrated that B-Eos
values were significantly higher in the high-FENO (35
ppb ) group than in the low-FENO group. Moreover,
FENO and B-Eos levels were significantly correlated.
FENO is known to reflect eosinophilic inflammation of
the airway while B-Eos reflects eosinophilic inflamma-
tion of the whole body. Although FENO and B-Eos are
considered independent risk factors for bronchial asthma,
asthma attacks, and wheezing,
１９
our findings suggests that
systemic eosinophilic inflammation may associate with
local eosinophilic inflammation of the airway.
Regarding adipocytokines, the serum adiponectin lev-
els were significantly lower in the high-FENO (35 ppb)
group than in the low-FENO group. Moreover, the uni-
variable odds ratio of the serum adiponectin levels for
high-FENO was 0.62 (95%CI 0.41-0.95), though the as-
sociation was not independent with B-Eos. These results
suggest that the serum adiponectin levels might associate
with eosinophilic inflammation of the airway.
The significant negative univariate correlation between
serum adiponectin levels and B-Eos suggests that a de-
crease in serum adiponectin levels is positively associ-
ated with eosinophilic inflammation of the whole body.
Zhu et al. have previously demonstrated that adiponectin
alleviates airway hyper-responsiveness, airway inflam-
mation, and oxidative stress in a murine model of
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Figure 2 Scatter plots illustrating univariate correlations between FENO and explanatory variables.
FENO, fractional exhaled nitric oxide.





















Although this mechanism has
not been proved in human model, our result suggests
similar mechanism exits in human.
Although increased serum leptin is a risk factor for
bronchial asthma in adult women,
１３
we did not find any
relationship between serum leptin level and FENO. The
likely reasons for this difference are as follows. First, the
duration of high serum leptin levels might have affected
the results. Second, no female subjects were included in
the high-FENO group in our study; therefore, we cannot
exclude the possibility that leptin may affect eosinophilic
inflammation of the airway in females.
Although PAI-1 was not significantly related to
FENO, it was significantly positively correlated with B-
Eos suggesting that PAI-1 may influence systemic
eosinophilic inflammation.
The MDA-LDL/LDL ratio had a significant positive
correlation with FENO and B-Eos. This result indicates
that oxidative stress may be positively associated with
eosinophilic inflammation of the airway and of the whole
body.
Visceral fat accumulation might induce changes in adi-
pocytokines, such as adiponectin and PAI-1, and oxida-
tive stress.
９，１５
Dekker et al. have reported that subcutane-
ous fat was not associated with FENO, while pre-
peritoneal fat was positively associated with FENO in
6,178 children aged 6 years.
２９
The decrease in serum adi-
ponectin levels and the increase in systemic oxidative
stress were associated with visceral fat accumulation.
３０
We have demonstrated that waist circumference, which
reflects visceral fat accumulation, tended to be higher in
the high-FENO group. We have also revealed the influ-
ence of serum adiponectin levels on eosinophilic inflam-
mation of the airway and the whole body. Additionally,
there was a significant correlation between the MDA-
LDL/LDL ratio and FENO. These data suggest that an
association between visceral fat accumulation and
eosinophilic inflammation of the airway and the whole
body. The change in fat distribution, especially visceral
fat accumulation in relation to obesity, may be one of the
critical factors that links childhood obesity to the devel-
opment of bronchial asthma in children and adolescents.
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Table　4　Univariable correlations between B-Eos and explanatory variables.
r p-value
BMI-z score 0.22 0.2
Waist circumference 0.2 0.2
Waist circumference/height ratio 0.2 0.2
Systolic blood pressure 0.054 0.7
Diastolic blood pressure 0.24 0.2




Leptin/adiponectin ratio 0.32 0.004*
PAI-1 0.42 0.006*
MDA-LDL cholesterol/LDL cholesterol ratio 0.33 0.04*
High-sensitivity CRP 0.24 0.1
HDL cholesterol -0.078 0.6




AST/ALT ratio -0.36 0.02*
γ-GTP 0.41 0.01*
Uric acid 0.21 0.2
HbA1c 0.17 0.3
Insulin 0.25 0.1
Blood glucose 0.049 0.8
B-Eos, blood eosinophil counts; BMI-z score, body mass index-z score; IgE, im-
munoglobulin E; PAI-1, plasminogen activator inhibitor-1; MDA-LDL, malondi-
aldehyde-modified low-density lipoprotein; LDL, low-density lipoprotein; CRP, 
C-reactive protein; HDL, high-density lipoprotein; TG, triglycerides; AST, aspar-
tate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl trans-
peptidase; HbA1c, hemoglobin A1c.
Our study had several limitations. First, because of the
small sample size, type II errors cannot be excluded, and
our study lacks statistical power. Second, we could not
detect a clear relationship between eosinophilic inflam-
mation and the duration of obesity or the change in vis-
ceral fat, adipocytokine, and oxidative stress because we
examined single factors in this study. Third, although we
used waist circumference, waist circumference/height ra-
tio, adiponectin, PAI-1, ALT, AST/ALT ratio, and γ-
GTP as markers of visceral fat, we had not performed X-
ray examinations to quantify visceral fat accumulation.
As a result, we cannot draw meaningful conclusions re-
garding an association between eosinophilic inflamma-
tion and visceral fat accumulation. Finally, the high-
FENO group did not include any female participants. Be-
cause our sample size was small and this was a cross-
sectional study, our findings cannot be used to determine
whether the reported gender differences resulted from co-
incidence or adipocytokine profiles.
Conclusions
In conclusion, eosinophilic inflammation might be asso-
ciated with a decrease in serum adiponectin levels which
might be induced by visceral fat accumulation. The pres-
ence of obesity alone is not a risk factor for eosinophilic
inflammation of the airway. Notably, visceral fat accu-
mulation might be a major cause of eosinophilic inflam-
mation. To elucidate the link between childhood obesity
and bronchial asthma, future research should examined
body fat distribution in addition to body weight and
BMI-z score among participants with obesity.
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Figure 3 Scatter plots illustrating univariate correlations between B-Eos and explanatory variables. 
B-Eos, blood eosinophil counts; IgE, immunoglobulin E; PAI-1, plasminogen activator inhibitor-1; 
MDA-LDL, malondialdehyde-modified low-density lipoprotein; LDL, low-density lipoprotein; ALT, 
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Table　5　Logistic regression model for the high-FENO (≥35 ppb) group.
Univariable Multivariable
Odds ratio 95% CI Odds ratio 95% CI
B-Eos (/10 μL) 1.068 1.015-1.12 1.055 1.0004-1.11
Adiponectin 0.62 0.41-0.95 0.7 0.45-1.09
FENO, fractional exhaled nitric oxide; CI, confidence interval; B-Eos, blood eosinophil counts.
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